Apollo Hospitals Enterprise Ltd. share price target

Q2FY19 results were operationally in line with I-direct estimates. However, net profit was lower mainly due to lower other income and higher tax rate (33% vs. I-direct estimate of 21%) Revenues grew 12.9% YoY to | 2090 crore (I-direct estimate: | 2092.4 crore) on the back of 16.4% YoY growth in pharmacy...

Standalone revenues grew 13.4% YoY to | 1910.4 crore (I-direct estimate: | 1921.6 crore) on the back of 16.7% YoY growth in the pharmacy business to | 892.1 crore (I-direct estimate: | 908.7 crore) and 10.7% YoY growth in the healthcare business to | 1019 crore (Idirect estimate: | 1013.2 crore) EBITDA margins improved 156 bps YoY to 11.9% (I-direct estimate: 11.5%) mainly due to lower other expenditure. EBITDA grew 30.5% YoY at | 226.7 crore (I-direct estimate: | 220.3 crore) Net profit grew 70.9% to | 60.2 crore (I-direct estimate: | 71.9 crore)...

Standalone revenues grew 12.1% YoY to | 1863 crore (I-direct estimate: | 1908 crore) on the back of 16.1% YoY increase in pharmacy business to | 863 crore (I-direct estimate: | 879 crore) and...

Apollo Hospitals' Q3FY18 revenue (adjusted for GST) increased 16% YoY to Rs 19 bn, while EBITDA increased 14% YoY to Rs 2.2 bn.

Revenues grew 13% YoY to | 1896 crore (I-direct estimate: | 1869 crore) on the back of 13% YoY increase in healthcare business to | 1008 crore (I-direct estimate: | 1009 crore) and 13% YoY increase in pharmacy business to | 888 crore (I-direct estimate: | 860 crore) EBITDA margins improved a mere 12 bps YoY to 11.7% (I-direct estimate: 12.5%). Higher gross margins were largely offset by higher employee cost and other expenditure. EBITDA increased 14% YoY at | 221 crore (I-direct estimate: | 234 crore)...

AHEL reported 13% YoY growth in standalone revenue in Q2FY18 driven by healthy growth in both healthcare services & pharmacy business. EBITDA margin declined by 163bps YoY in Q2FY18 despite healthy revenue growth primarily on account of low occupancy rate in newly added hospitals, loss in Navi Mumbai unit and impact of stent price regulation. Though consolidated EBITDA margin is expected to grow modestly in FY18E due to loss in Navi Mumbai hospital and impact of stent price regulation, however the same is expected to improve to 11.3%/12.3% in FY19E/20E....

ICICI Securities Ltd | Retail Equity Research Revenues increased 13% YoY to | 1852 crore (I-direct estimate: | 1835 crore) led by 11% YoY increase in healthcare business to | 1024 crore (I-direct estimate: | 1002 crore) and 17% YoY increase in pharmacy business to | 828 crore (I-direct estimate: | 794 crore) EBITDA margins declined 163 bps YoY to 11.9% (I-direct estimate: 12.1%) mainly due to higher employee and other expenditure. EBITDA remained flat YoY at | 221 crore...

Revenue grew by 1.37% to Rs. 1684.46 Cr in Q1FY18 when compared to the previous quarter Revenue grew by 1.37% to Rs. 1684.46 Cr in Q1FY18 when compared to the previous quarter

Revenues increased 15% YoY to | 1685 crore (I-direct estimate: | 1712 crore) on the back of 11% increase in healthcare business to | 920 crore (I-direct estimate: | 939 crore) and 21% increase in pharmacy business to | 764 crore (I-direct estimate: | 773 crore) EBITDA margins declined 252 bps YoY to 10.3% (I-direct estimate: 10.6%) mainly due to an adverse segment mix. EBITDA declined 8% YoY to | 174 crore (I-direct estimate: | 181 crore) Adjusted net profit declined 51% to | 35 crore (I-direct estimate: | 54...

Apollo Hospital's FY17 earnings miss (EBITDA at Rs 7.3 bn vs. our expectation of Rs 7.8 bn) was largely due to lower than expected margin in matured hospitals.